#USA #New York #Class Action #Faruqi Faruqi #Aquestive Therapeutics

Securities Class Action Alert

Important Update for Investors in Aquestive Therapeutics

As the legal landscape continues to evolve, investors in Aquestive Therapeutics, Inc. should be aware of a significant deadline approaching on May 4, 2026. This date marks the last opportunity for individuals who purchased shares of Aquestive between June 16, 2025, and January 8, 2026, to join a federal securities class action lawsuit. This litigation has been initiated to address allegations against the company regarding the handling of its New Drug Application (NDA) for its product Anaphylm, especially in regards to misleading statements made to investors.

Background of the Class Action

The firm leading this investigation, Faruqi & Faruqi, LLP, has a long-standing reputation in the realm of securities law and has been pivotal in recovering substantial amounts for investors since 1995. Allegations suggest that Aquestive Pharmaceuticals made false statements surrounding the safety and efficacy of Anaphylm, particularly by failing to disclose essential information about its NDA review by the FDA. This failure culminated in significant financial losses for many shareholders when the company's stock prices plummeted following an announcement by the CEO in early January.

The Lawsuit's Specific Allegations

On January 9, 2026, the FDA informed Aquestive that there were deficiencies in the NDA that barred any discussion on labeling and post-marketing commitments. This disclosure led to a stark drop in stock prices, showcasing the tangible impact of the alleged misinformation. Investors who believe their rights were compromised during this period can explore their legal options through this ongoing class action suit, potentially becoming lead plaintiffs and representing the wider class of affected stakeholders.

Taking Action: What Investors Should Do

Investors are encouraged to contact Faruqi & Faruqi directly for guidance. Those who wish to join the suit can reach out to Senior Partner Josh Wilson at the provided phone numbers. The opportunity to act is vital, especially as becoming a lead plaintiff could influence the course of the litigation and lead to a greater recovery if a favorable resolution is reached.

The Importance of Being Informed

In an ever-changing market, staying informed is critical. Current and potential investors must remain vigilant about potential legal ramifications of corporate actions. Faruqi & Faruqi, LLP also encourages anyone with additional information regarding Aquestive's practices, including whistleblowers, to come forward. This collective knowledge can significantly impact the strength and direction of the class action lawsuit.

Conclusion

As investors await developments, there is a pressing need to understand one's legal rights as shareholders of Aquestive Therapeutics. May 4, 2026, marks a critical point in this narrative, urging those affected to act promptly and diligently to safeguard their financial interests. The outcome of this lawsuit may not only affect individual investors but could also reshape the investment landscape for pharmaceutical companies regarding transparency and accountability with shareholders. For more information or to discuss your options, visit Faruqi & Faruqi's dedicated class action page.